PASG (Passage Bio) PEG Ratio: 0.00 (As of Jul. 03, 2026)


PASG Passage Bio Inc PASG
30 GF Score
Price $4.63
! 2 Warning Signs
View Full Analysis

What is Passage Bio PEG Ratio?

Passage Bio PASG +2.18% 30 PEG Ratio is 0.00 as of Jul. 03, 2026. GuruFocus rates PASG with a GF Score™ of 30/100. The stock has 2 warning signs investors should review. Among 95 Biotechnology companies, Passage Bio ranks worse than 1052630.53% on this metric.

PE Ratio without NRI / 5-Year EBITDA Growth Rate*

PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The growth rate we use is the 5-Year EBITDA growth rate. As of today, Passage Bio's PE Ratio without NRI is 0.00. Passage Bio's 5-Year EBITDA growth rate is 27.30%. Therefore, Passage Bio's PEG Ratio for today is 0.00.

* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.


The historical rank and industry rank for Passage Bio's PEG Ratio or its related term are showing as below:



PASG's PEG Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 2.02
* Ranked among companies with meaningful PEG Ratio only.

Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.


Passage Bio  (NAS:PASG) PEG Ratio Explanation

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.


Passage Bio PEG Ratio Related Terms


Passage Bio PEG Ratio Historical Data

* Premium members only.

The historical data trend for Passage Bio's PEG Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Passage Bio PEG Ratio Chart

Passage Bio Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
PEG Ratio
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Passage Bio Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
PEG Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

PASG vs CTXR, HIND, GTBP: PEG Ratio Comparison

For the Biotechnology subindustry, Passage Bio's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Passage Bio PEG Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Passage Bio's PEG Ratio distribution charts can be found below:

* The bar in red indicates where Passage Bio's PEG Ratio falls into.


PASG
30GF Score
Passage Bio Inc PASG
PEG Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Passage Bio PEG Ratio Calculation

PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The ratio we use is the 5-Year EBITDA growth rate.

Passage Bio's PEG Ratio for today is calculated as

PEG Ratio=PE Ratio without NRI/5-Year EBITDA Growth Rate*
=/27.30
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.

Frequently Asked Questions Learn more about PEG Ratio →
What does a PEG Ratio of 0.00 mean?
Passage Bio (PASG) has a PEG Ratio of 0.00 as of Jul. 03, 2026. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Passage Bio and its competitors. According to the industry distribution chart, Passage Bio ranks #999999 out of 95 companies in the Biotechnology industry.
Is Passage Bio's PEG Ratio too high?
Passage Bio's current PEG Ratio is 0.00. Based on the distribution chart, Passage Bio ranks #999999 out of 95 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Passage Bio has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Passage Bio's PEG Ratio compare to CTXR and HIND?
According to the Biotechnology industry distribution chart, Passage Bio ranks #999999 out of 95 companies for PEG Ratio. This places Passage Bio in the lower half of its industry. The industry median PEG Ratio is 2.02. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PEG Ratio for a Biotechnology company?
The median PEG Ratio among Biotechnology companies is 2.02, based on 95 companies in the industry. Companies in the top quartile (top 25%) have a PEG Ratio significantly above this median, while those in the bottom quartile fall well below. However, PEG Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PEG Ratio mean?
A high PEG Ratio can signal that a stock is expensive relative to its fundamentals. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Passage Bio and its competitors. For the Biotechnology industry, the median PEG Ratio is 2.02 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Passage Bio's current PEG Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Passage Bio stock overvalued right now?
Passage Bio (PASG) has a current PEG Ratio of 0.00. The current PEG Ratio is 0.00. Passage Bio's overall GF Score™ is 30/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PEG Ratio calculated?
PEG Ratio is calculated from a company's financial statements. For Passage Bio (PASG), the current PEG Ratio is 0.00 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Passage Bio Business Description

Address 2005 Market Street, 39th Floor, One Commerce Square, Philadelphia, PA, USA, 19103
Passage Bio Inc is a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases. Their primary focus is the development and advancement of cutting-edge, one-time gene therapies designed to target critical underlying pathologies in these conditions. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target the critical underlying pathology of neurodegenerative diseases. The pipeline having PBFT02.
30GF Score

Get the complete analysis for PASG

PEG Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.63
Price